Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management

  • Potential for prophylaxis

  • PfPI4K inhibitor

Key features
  • 80mg dose predicted to give coverage above Minimal Parasiticidal Concentration for ≥8 days
  • Good prophylactic activity against P. cynomolgiin vivo, after single dose
  • Long half-life in human
  • Potential for transmission-blocking activity in a Standard Membrane Feeding Assay
  • Safety in pregnancy

  • Phase IIa in Ethiopia ongoing
Next milestone
  • Initiate recruitment of P. falciparum patients cohort in phase IIa
  • Name MMV390048: Discovery and phase I partnership between MMV and H3D, University of Cape Town

MMV Project Director
  • Dr Cristina Donini